Healthcare Industry News: Vinorelbine
News Release - June 14, 2006
Novacea Appoints John Walker to Board of DirectorsSOUTH SAN FRANCISCO, CA--(Healthcare Sales & Marketing Network)--Jun 14, 2006 -- Novacea, Inc. (NasdaqNM:NOVC ) announced today the appointment of John P. Walker to the company's board of directors. Mr. Walker currently serves as chairman of the boards of directors for Renovis Inc., KAI Pharmaceuticals, Guava Technologies and Saegis Pharmaceuticals. He serves on the boards of directors for Geron Corporation and several privately-held biotechnology companies.
During his 35-year career, Mr. Walker has served as CEO or interim CEO of a number of biotechnology and pharmaceutical companies, including Chairman and interim CEO of KAI Pharmaceuticals, interim CEO of Guava Technologies, Chairman and CEO of Bayhill Therapeutics, and Chairman and interim CEO of Centaur Pharmaceuticals, Inc. From 1993 to 2001, he was Chairman, CEO, and a director of AXYS Pharmaceuticals, Inc. and its predecessor company Arris Pharmaceutical Corporation. Prior to Arris, Mr. Walker was Chairman and CEO of Vitaphore Corporation, a biomaterials company that was sold to Union Carbide Chemical and Plastics Company, Inc.
Additionally, Mr. Walker has served as a venture partner with Morgan Stanley Venture Partners and as an investment advisor to MDS Capital Corporation. Mr. Walker began his career with American Hospital Supply Corporation, where he held a variety of general management, sales, and operational positions and served as President of American Medical Systems and The Hospital Company.
Mr. Walker holds a bachelor's degree in history from The State University of New York at Buffalo and is a graduate of the Advanced Executive Program, J. L. Kellogg Graduate School of Management at Northwestern University.
Novacea, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing novel cancer therapies. Novacea has three product candidates in clinical trials, including DN-101, which currently is in a Phase 3 clinical trial for androgen-independent prostate cancer, or AIPC. Novacea's second drug candidate, oral Vinorelbine, is expected to enter a registration trial for metastatic breast cancer in the second half of 2006. Novacea's third product candidate, AQ4N, is expected to advance into a Phase 1/2 clinical trial in the second half of 2006 for glioblastoma multiforme in combination with radiation and chemotherapy.
Note: Except for the historical information contained herein, the matters set forth in this press release, including statements as to development, clinical studies, regulatory review and approval, and commercialization of products, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: early stage of development; the focus, conduct, enrollment and timing of our clinical trials; regulatory review and approval of product candidates; commercialization of products; market acceptance of products; funding requirements; intellectual property protection for our product candidates; competing products and other risks detailed from time to time under the heading "Risk Factors" in our most recent Registration Statement on Form S-1, as amended, and as may be updated from time to time by our future filings under the Securities Exchange Act. If one or more of these risks or uncertainties materialize, or if any underlying assumptions prove incorrect, our actual performance or results may vary materially from any future performance or results expressed or implied by these forward-looking statements. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.